Cardiff Lexington Corp (CDIX) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Cardiff Lexington Corp $0.04, price $0.06, upside -32.0%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $0.0600 – $2,858 · fair‑value band $0.0306 – $0.0459 · the $0.0600 price screens above the $0.0408 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Cardiff Lexington in your weekly email
Every Wednesday you see whether Cardiff Lexington is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate.
Show more
Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate. The company provides diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. It also engages in real estate business. The company also offers orthopedic and pain procedure services, including hip and knee replacement, shoulder reconstruction, fracture care, and hand surgery, as well as spinal surgery. It serves personal injury attorneys, insurance carriers, physical therapy providers, and chiropractic care providers. The company was formerly known as Cardiff International, Inc. and changed its name to Cardiff Lexington Corporation in January 2018. Cardiff Lexington Corporation is based in Lexington, Kentucky.
Stock analysis
Cardiff Lexington Corp (CDIX) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0408, 32.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $0.2400 per share, and 1 of the 3 models we run sit above the $0.0600 price.
Bear case: the Dividend Discount group reads lowest at $0.0500, and 2 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0306 (bear) to $0.0459 (bull), the price of $0.0600 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Cardiff Lexington Corp reported revenue of $11.5M in FY2025 versus $10.0M in FY2021, a compound +3.6%/yr. Reported net income was −$6.5M in FY2025.
Key figures
Market cap $916K · P/S ratio 0.09 · EPS (TTM) $−1.00 · Dividend yield 5.3% · Net margin −56.7% · Return on equity −202% · Return on assets (EBIT) 14.4% · Operating margin −25.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 99% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −32%, CDIX screens richer than that median.
Fair Value models
Bear $0.0306Fair Value $0.0408Bull $0.0459
Price $0.0600 · Upside -32.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+39.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Start year 2020 (pandemic). Over 10 years: +23.6% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+108.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−34.3% (2019) → −2.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−32.0% · Below median
Profitability
Return on assets−2.4% · Bottom 25%
Net margin (TTM)−92.1% · Bottom 25%
Operating margin (TTM)−25.2% · Bottom 25%
Growth and dividend
Revenue growth−22.6% · Bottom 25%
Dividend yield (TTM)5.3% · Top 25%
Balance sheet
Debt / equity0.03× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B0.17× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.09× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 26
PAST (return on equity)0· sector 32
HEALTH (low debt)99· sector 90
DIVIDEND (yield)100· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cardiff Lexington Corp (CDIX) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.0408 versus a price of $0.0600, about −32% upside (overvalued).
What is the fair value of CDIX?
Our model-based fair value for Cardiff Lexington Corp is $0.0408 (as of Oct 4, 2026), built from audited fundamentals. The current price: $0.0600.
What is the quality score of CDIX?
Cardiff Lexington Corp has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cardiff Lexington Corp (CDIX)?
Our model-based price target is the fair value of $0.0408 (as of Oct 4, 2026) from 3 valuation models. Cautious scenario $0.0306, optimistic scenario $0.0459. It is a calculation from audited fundamentals, not an analyst target.
What is the Cardiff Lexington Corp stock forecast for 2026?
Our models put fair value at $0.0408, about −32% upside versus a price of $0.0600 (overvalued). Cautious scenario $0.0306, optimistic scenario $0.0459. The calculation is refreshed regularly with new filings.
What is the revenue of Cardiff Lexington Corp (CDIX)?
Cardiff Lexington Corp reported trailing-twelve-month revenue of about $10.2M (latest available figure, as of Oct 4, 2026).
Does Cardiff Lexington Corp pay a dividend?
Cardiff Lexington Corp currently shows a dividend yield of about 5.33% relative to its recent price (as of Oct 4, 2026).
What is the intrinsic value of Cardiff Lexington Corp (CDIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cardiff Lexington Corp it is $0.0408 per share (as of Oct 4, 2026), against a price of $0.0600. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Cardiff Lexington Corp stock overvalued or undervalued in 2026?
As of Oct 4, 2026, CDIX trades above its calculated fair value: price $0.0600, fair value $0.0408, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CDIX?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0408). For Cardiff Lexington Corp the two are $0.0192 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cardiff Lexington Corp worth?
The market values Cardiff Lexington Corp at about $916K (market capitalisation, as of Oct 4, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0408 per share.
What do the bullish and bearish scenarios say about CDIX?
Our models span a range for Cardiff Lexington Corp: cautious scenario $0.0306, base $0.0408, optimistic $0.0459 per share (as of Oct 4, 2026, price $0.0600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cardiff Lexington Corp (CDIX)?
Balance-sheet figures for Cardiff Lexington Corp (as of Oct 4, 2026): return on equity −201.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is CDIX from its 52-week high?
Cardiff Lexington Corp trades at $0.0600, about 99% below its 52-week high of $5.62 and at the low of $0.0600 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0408 is for.
Which stocks are comparable to Cardiff Lexington Corp?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cardiff Lexington Corp stock attractive at the current price?
The data as of Oct 4, 2026: price $0.0600, calculated fair value $0.0408 (−32%), Quality Score 23/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CDIX calculated?
We run Cardiff Lexington Corp through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0408, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Cardiff Lexington Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cardiff Lexington Corp (CDIX)?
The closing price on Oct 2, 2026 was $0.0600. Our model-based fair value is $0.0408, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cardiff Lexington Corp right now?
The price sits above even our optimistic bull case ($0.0459). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Cardiff Lexington Corp
How large is the market capitalisation of Cardiff Lexington Corp (CDIX)?
The market capitalisation of Cardiff Lexington Corp is $916K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cardiff Lexington Corp (CDIX)?
The price-to-sales ratio of Cardiff Lexington Corp is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cardiff Lexington Corp (CDIX)?
Earnings per share at Cardiff Lexington Corp are $−1.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cardiff Lexington Corp (CDIX)?
The dividend yield of Cardiff Lexington Corp is 5.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cardiff Lexington Corp (CDIX)?
The net margin of Cardiff Lexington Corp is −56.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cardiff Lexington Corp (CDIX)?
The return on equity (ROE) of Cardiff Lexington Corp is −202% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cardiff Lexington Corp (CDIX)?
On an EBIT basis the return on assets of Cardiff Lexington Corp is 14.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cardiff Lexington Corp (CDIX)?
The operating margin of Cardiff Lexington Corp is −25.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cardiff Lexington Corp (CDIX)?
Revenue at Cardiff Lexington Corp is growing −22.6% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cardiff Lexington Corp (CDIX)?
Earnings per share at Cardiff Lexington Corp are growing +19.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cardiff Lexington Corp (CDIX) generate?
The free cash flow of Cardiff Lexington Corp is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cardiff Lexington Corp (CDIX) carry?
The net debt of Cardiff Lexington Corp is $18.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cardiff Lexington Corp in the live analysis
One click puts Cardiff Lexington Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 4, 2026